WO1993009773A1 - Composition servant a prevenir ou a traiter la dysmenorrhee et aliment ayant une fonction de prevention de la dysmenorrhee - Google Patents
Composition servant a prevenir ou a traiter la dysmenorrhee et aliment ayant une fonction de prevention de la dysmenorrhee Download PDFInfo
- Publication number
- WO1993009773A1 WO1993009773A1 PCT/JP1992/001507 JP9201507W WO9309773A1 WO 1993009773 A1 WO1993009773 A1 WO 1993009773A1 JP 9201507 W JP9201507 W JP 9201507W WO 9309773 A1 WO9309773 A1 WO 9309773A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dysmenorrhea
- preventing
- epa
- acid
- dha
- Prior art date
Links
- 206010013935 Dysmenorrhoea Diseases 0.000 title claims abstract description 38
- 208000005171 Dysmenorrhea Diseases 0.000 title claims abstract description 30
- 235000013305 food Nutrition 0.000 title abstract description 5
- 230000003449 preventive effect Effects 0.000 title abstract description 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims abstract description 38
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims abstract description 31
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 13
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims abstract description 11
- 229940090949 docosahexaenoic acid Drugs 0.000 claims abstract description 11
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 235000013376 functional food Nutrition 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 3
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 150000003904 phospholipids Chemical class 0.000 claims description 2
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000003925 fat Substances 0.000 claims 1
- 235000019197 fats Nutrition 0.000 claims 1
- -1 if necessary Substances 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims 1
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 abstract 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 abstract 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 235000013310 margarine Nutrition 0.000 description 4
- 239000003264 margarine Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000006957 competitive inhibition Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000003821 menstrual periods Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- UOORRWUZONOOLO-OWOJBTEDSA-N (E)-1,3-dichloropropene Chemical compound ClC\C=C\Cl UOORRWUZONOOLO-OWOJBTEDSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 102000011730 Arachidonate 12-Lipoxygenase Human genes 0.000 description 1
- 108010076676 Arachidonate 12-lipoxygenase Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Definitions
- the first invention for which a patent is sought is Eicosapenic acid
- a composition for preventing or treating dysmenorrhea which comprises at least one or more of sahexenaic acid or a derivative thereof as an active ingredient.
- Vitamin E ⁇ -tocopherol
- the pharmacological effect of preventing or treating dysmenorrhea which has been considered difficult in the past, can be realized by simply administering the pharmacological effect.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Composition servant à prévenir ou à traiter la dysménorrhée, produit préventif ou curatif contre la dysménorrhée, obtenu par l'incorporation de la composition dans une préparation pharmaceutique, et aliment ayant une fonction de prévention de la dysménorrhée. La composition contient en tant qu'ingrédient actif au moins un élément sélectionné parmi l'acide eicosapentaénoïque (EPA), l'acide docosahexaénoïque (DHA) et leurs dérivés, et se fonde sur la découverte que l'EPA et le DHA sont utiles pour traiter la dysménorrhée, notamment la dysménorrhée primaire.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP32945891A JP3177686B2 (ja) | 1991-11-18 | 1991-11-18 | 月経困難症予防または治療剤と月経困難症予防機能性食品 |
| JP3/329458 | 1991-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1993009773A1 true WO1993009773A1 (fr) | 1993-05-27 |
Family
ID=18221605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP1992/001507 WO1993009773A1 (fr) | 1991-11-18 | 1992-11-18 | Composition servant a prevenir ou a traiter la dysmenorrhee et aliment ayant une fonction de prevention de la dysmenorrhee |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP3177686B2 (fr) |
| WO (1) | WO1993009773A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015198054A1 (fr) * | 2014-06-27 | 2015-12-30 | The University Court Of The University Of Edinburgh | Nouveau traitement pour endométriose |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54117035A (en) * | 1978-01-23 | 1979-09-11 | Verronmay Ltd | Medical and food composition |
| JPS6216415A (ja) * | 1985-07-04 | 1987-01-24 | エフアモル・リミテツド | 月経前症候群治療用医薬組成物およびその治療方法 |
| JPS6281310A (ja) * | 1985-10-02 | 1987-04-14 | Agency Of Ind Science & Technol | ガンマリノレン酸含有ドリンク剤 |
-
1991
- 1991-11-18 JP JP32945891A patent/JP3177686B2/ja not_active Expired - Fee Related
-
1992
- 1992-11-18 WO PCT/JP1992/001507 patent/WO1993009773A1/fr active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54117035A (en) * | 1978-01-23 | 1979-09-11 | Verronmay Ltd | Medical and food composition |
| JPS6216415A (ja) * | 1985-07-04 | 1987-01-24 | エフアモル・リミテツド | 月経前症候群治療用医薬組成物およびその治療方法 |
| JPS6281310A (ja) * | 1985-10-02 | 1987-04-14 | Agency Of Ind Science & Technol | ガンマリノレン酸含有ドリンク剤 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015198054A1 (fr) * | 2014-06-27 | 2015-12-30 | The University Court Of The University Of Edinburgh | Nouveau traitement pour endométriose |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3177686B2 (ja) | 2001-06-18 |
| JPH05139966A (ja) | 1993-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5441287B2 (ja) | 心血管事象を予防するための必須脂肪酸 | |
| AU2001286576B2 (en) | Composition and method for treatment of hypertriglyceridemia | |
| Kapoor et al. | Coenzyme Q10-a novel molecule | |
| US5436269A (en) | Method for treating hepatitis | |
| JP2008521863A (ja) | Ｈｉｖ感染患者における抗レトロウイルス治療がひき起こす高コレステロール血症の治療のためのオメガ−３脂肪酸の利用 | |
| UA76108C2 (en) | Use of therapeutic combination of fatty acids | |
| KR20080024511A (ko) | 심혈관 이벤트 발병 예방용 조성물 | |
| HUE028065T2 (en) | Preparations for the treatment of neurological disorders | |
| EP2675445A1 (fr) | Statine et acides gras oméga-3 (epa, dha et dpa) utilisés dans les maladies cardiovasculaires | |
| US8206759B2 (en) | Method of reducing blood cholesterol and triglyceride levels using combinations of vasoprotective agent | |
| JPS6377817A (ja) | 治療用組成物 | |
| EP0201159A2 (fr) | Compositions pharmaceutiques et diététiques contenant des acides linoléniques pour le traitement de l'hypertrophie prostatique bénigne | |
| JPH0825876B2 (ja) | 面皰治療剤組成物 | |
| HUP0201667A2 (en) | Oral form of administration | |
| WO1993009773A1 (fr) | Composition servant a prevenir ou a traiter la dysmenorrhee et aliment ayant une fonction de prevention de la dysmenorrhee | |
| WO2012112511A1 (fr) | Inhibiteur de l'absorption du cholestérol (azétidinone) et acides gras oméga 3 (epa, dha, dpa) pour la réduction du cholestérol et pour la réduction des événements cardiovasculaires | |
| US9248138B2 (en) | Process and composition for stabilization of vulnerable plaque utilizing a combination of a statin and omega 3 fatty acids | |
| JPH04169524A (ja) | 血清脂質改善作用を有する組成物 | |
| JPS5978118A (ja) | 血栓症治療および予防剤 | |
| AU2005244483B2 (en) | Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease | |
| JP2000044470A (ja) | 高脂血症薬 | |
| JPS6011421A (ja) | 血中脂質降下剤 | |
| JP2007532605A5 (fr) | ||
| HK1090519B (en) | Combinations of vasoprotective agents and formulations containing them | |
| WO2015106177A1 (fr) | Procédé et composition de stabilisation de plaques vulnerables à l'aide d'une combinaison composée d'une statine et d'acides gras omega 3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): SE US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 122 | Ep: pct application non-entry in european phase |